Naslov
Olanzapine in the treatment of psychosis in advanced Parkinson's disease

Autori
Relja, Maja

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
Journal of Neural Transmission / Carlsson A - Beč : Springer, 2000, XXXVII-XXXVII

Skup
Fith Congress European Society for Clinical Neuropharmacology

Mjesto i datum
Opatija, Hrvatska, 17.05.2000. - 21.05.2000

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
olanzapine; psychosis; Parkinson's disease

Sažetak
Advanced Parkinson's disease (PD) is often complicated by hallucinations and delusions. Olanzapine (OLZ), a new atypical neuroleptic with a different dopamine receptors site affinity than clozapine, has been used in the treatment of psychosis in PD patients.However, contradictory results have been reported about worsening of PD motor features during OLZ administration. We started OLZ therapy in nine PD patients (age range 53-71 years, disease duration:7-13 years) who developed severe hallucinations and delusions. Patients were commenced on 2.5 mg OLZ at night and the dose titration to a maximum of 5.0 mg until the symptomes were aboliched (14 days to four months). All patients had a positive response with decreased psychosis.Eight patients had no increase in parkinsonism as assesed by the motor part of Unifed Parkinson's Disease Rating Scale (UPDRS). However, only one patient had increased UPDRS score.Our preliminary results indicate that OLZ should be considered for the treatment of psychosis in selected PD patients.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA